Healthtech Solutions (OTC: HLTT), the parent company of Varian Biopharmaceuticals Inc., Medi-Scan Inc. and RevHeart Inc., has announced its appointment of Edward (“Ned”) Swanson, M.D., as its chief executive officer. Dr. Swanson brings a unique background and skillset that is particularly well suited to lead Healthtech, combining scientific, clinical and industry knowledge. He is a co-founder of PolarityTE Inc., a biotech company developing various regenerative tissue products and biomaterials, led by its flagship product SkinTE(R). In his leadership roles with PolarityTE and its subsidiaries, Dr. Swanson gleaned deep industry knowledge and know-how related to company formation, financing, product development, medical and regulatory affairs, manufacturing, business development, and commercialization within health care. “With Ned Swanson at the helm of Healthtech Solutions, we have the leadership and expertise of an individual who has demonstrated success at both medical bioengineering and effective public company stewardship at C-level,” said Healthtech Solutions Chairman David Rubin. “His direction will facilitate a rise to a new level for the company and serve to deliver continued growth and shareholder value.”
To view the full press release, visit https://nnw.fm/iNlEe
About Healthtech Solutions Inc.
Healthtech Solutions is a reporting public company. The board of directors is focusing the company’s resources into creating a platform to acquire and/or invest in cutting-edge health care technology in the medical device biopharma and pharmaceutical fields. The goal is to bring these solutions to market.
To date, Healthtech Solutions has invested in three areas of medical technology breakthrough:
- Medi-Scan Inc., which is developing a technology that converts 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The goal is a commercial system that can provide the data equivalent to an X-ray, MRI or CT scan, without radiation and at a lower cost.
- RevHeart Inc., which is advancing critical research into the treatment of COVID-related heart muscle injury.
- Varian Biopharmaceuticals Inc., a precision oncology company, is the first acquisition of Healthtech Oncology Inc.
Healthtech Solutions has a pipeline of additional acquisitions currently under due diligence.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://nnw.fm/HLTT
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork